Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ÆÄ¸Ó½´Æ¼Äà > ½Å°æÁúȯ > 2013³â±îÁöÀÇ ÅðÇ༺ ½Å°æÁúȯ ½ÃÀå ¿¹Ãø
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4905)
°¨¿°Áúȯ (349)
°ñÁúȯ Ä¡·á (38)
´ç´¢º´ (194)
¹é½Å (181)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (44)
ºñó¹æ ÀǾàǰ (152)
¼öÀÇÇÐ (18)
½Å°æÁúȯ (174)
½Å¾à°³¹ß (1503)
¾ÏÄ¡·á (932)
¾à¹°Àü´Þ (185)
ÀǾàǰ ±ÔÁ¦È¯°æ (132)
Á¤½ÅÁúȯ (86)
Á¦³×¸¯ ÀǾàǰ (128)
Á¦¾àȸ»çºÐ¼® (525)
󹿾à (165)
½ÃÀ庸°í¼­

2013³â±îÁöÀÇ ÅðÇ༺ ½Å°æÁúȯ ½ÃÀå ¿¹Ãø

Neurodegenerative Market Forecast to 2013

¸®¼­Ä¡»ç Cutting Edge Information
¹ßÇàÀÏ 2009³â 02¿ù »óǰÄÚµå 82015
ÆäÀÌÁö Á¤º¸ 201 Pages
°¡°Ý
US $ 6,995 £Ü 8,363,200 PDF by E-mail (Single User License)
US $ 20,995 £Ü 25,101,600 PDF By E-mail (Multi User License)


Cutting Edge Information ¿¡¼­ 2009³â 02¿ù ¿¡ ¹ßÇàÇÑ ¡¸2013³â±îÁöÀÇ ÅðÇ༺ ½Å°æÁúȯ ½ÃÀå ¿¹Ãø¡¹ º¸°í¼­´Â 201 Pages·Î ±¸¼ºµÇ¾î, US $6,995 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

ÅðÇ༺ ½Å°æÁúȯ Ä¡·á¾àÀÇ °³¹ß µ¿Çâ°ú °æÇÕ, Àü·«Àû Æ÷Áö¼Å´×°ú ÇÔ²² ½ÃÀå ¼ºÀå±âȸ, ÀÓ»ó½ÃÇè µ¿Ç⠵ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

    1. °³¿ä
    • Á¶»ç¹æ¹ý
    • ÅðÇ༺ ½Å°æÁúȯ ½ÃÀå µ¿Çâ
    • ¹æ¹ý·Ð°ú Á¤ÀÇ
    2. ¾ËÃ÷ÇÏÀ̸Ӻ´
    • ¾Æ¼¼Æ¿Äݸ°¿¡½ºÅ×¶ó¾ÆÁ¦ ¾ïÁ¦Á¦
      • Aricept
      • Exelon
      • Razadyne
    • NMDA ±æÇ×Á¦
      • Namenda
      • Ebixa
    • ¾Æ¹Ð·ÎÀÌµå º£Å¸ Ä¡·á
      • Bapineuzumab
      • LY450139
      • LY2062430
      • ACC-001
    • ±âŸ ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·á
    3. ´Ù¹ß¼º°æÈ­Áõ
    • ÀÎÅÍÆä·Ð º£Å¸
      • Avonex
      • Rebif
      • Betaseron
    • ¸é¿ªÁ¶ÀýÁ¦
      • Copaxone
      • Fingolimod/FIY720
      • BG-12
      • Laquinimod
      • °æ±¸ Leustatin
      • Teriflunomid/HMR1726
    • ´ÜÀÏŬ·ÐÇ×ü
      • HuMax-CD20
      • Campath
      • Rituxan/MabThera
      • Tysabri/Antegren
      • Firategrast/SB683699
    • ±âŸ Ä¡·á¹ý
    4. ÆÄŲ½¼º´
    • µµÆÄ¹Î ÀÛ¿ë¾à
      • Comtan
      • mirapex
      • Sinemet
      • Apokyn
      • Requib XL
    • ±âŸ Ä¡·á¹ý
      • Azilect/Agilect
      • ACP-103
      • Droxidopa
    5. µµÇ¥
ksm
Back to Top